n.a. (PCYC)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

Today's spike in oil prices was even strong enough to embolden money managers to do some buying, Cramer says.

AXON, REGN, BURL, FIVE: Jim Cramer's Views

AXON, REGN, BURL, FIVE: Jim Cramer's Views

Jim Cramer shares his views on the latest moves in biotech and retail. Account, Regeneron, Burlington Stores and Five Below are among the many stocks discussed here.

The 10 Biggest U.S. M&A Deals in 2015

The 10 Biggest U.S. M&A Deals in 2015

Health care deals dominate the list of big mergers so far this year, while tech comes in second.

Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck

Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck

Jim Cramer likes the 10 early-stage drugs J&J has in its pipeline, among other reasons.

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.

New Lifetime High For Pharmacyclics (PCYC)

New Lifetime High For Pharmacyclics (PCYC)

Trade-Ideas LLC identified Pharmacyclics (PCYC) as a new lifetime high candidate

Jim Cramer -- Why Is Janet Yellen Suddenly a Stock Commentator?

Jim Cramer -- Why Is Janet Yellen Suddenly a Stock Commentator?

The Fed chief used some pretty frightening terms about stocks Wednesday, saying that valuations 'generally are quite high' and that there are 'potential dangers' with them.

First-Quarter Deals Near $1 Trillion Mark Highest Value Since 2007

First-Quarter Deals Near $1 Trillion Mark Highest Value Since 2007

Mega deals from strategic players across a variety of industries pushed first-quarter deals to the highest value since 2007.

Earnings Growth Boosts AbbVie

Drug franchises are still going strong.

Jim Cramer -- Mylan's Move to Acquire Perrigo a Prescription for Success

Jim Cramer -- Mylan's Move to Acquire Perrigo a Prescription for Success

The drug companies' strengths in generics and knocks-off drugs should complement one another.

Mylan Bids $29 Billion for Perrigo in Latest Big Pharma Deal

Mylan Bids $29 Billion for Perrigo in Latest Big Pharma Deal

Mylan made public on Wednesday that it had made a proposal to acquire generic drugmaker Perrigo in a deal valued at $205 per share in cash and stock.

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.

Biotech, Chips Stand Their Ground; Be Careful What You Wish For: Jim Cramer's Best Blogs

Biotech, Chips Stand Their Ground; Be Careful What You Wish For: Jim Cramer's Best Blogs

Catch up on Jim Cramer's thinking over the last week about two leadership groups that have been hammered and the spike in oil.

BioMarin Rises Amid Takeover Speculation, Price Target Raises

BioMarin Rises Amid Takeover Speculation, Price Target Raises

The shares of BioMarin are climbing after a blog reported last night that Shire is considering offering to acquire the company.

3 Stocks Reiterated As A Hold: PCYC, LNKD, PM

3 Stocks Reiterated As A Hold: PCYC, LNKD, PM

TheStreet Ratings team reiterated 3 stocks with a hold rating on Thursday

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.

Jim Cramer on Biotech Stocks the Market Always Seems to Undervalue

Jim Cramer on Biotech Stocks the Market Always Seems to Undervalue

It shouldn't be possible, but it never seems too late to get in.

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

It's creating investment opportunities that just shouldn't exist, Cramer says.

Jim Cramer's Trust Sells Out of AbbVie: What Wall Street's Saying

Jim Cramer's Trust Sells Out of AbbVie: What Wall Street's Saying

Jim Cramer's charitable trust closed out its position in AbbVie on Tuesday, citing concerns for its 'expensive' acquisition plans for Pharmacylics.

PHARMACYCLICS INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To AbbVie

PHARMACYCLICS INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To AbbVie

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Pharmacyclics...

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Pharmacyclics Inc. Of Commencement Of Class Action Investigation Concerning The Fairness Of The Sale Of The Company To AbbVie

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Pharmacyclics Inc. Of Commencement Of Class Action Investigation Concerning The Fairness Of The Sale Of The Company To AbbVie

The following statement is being issued by Levi & Korsinsky, LLP: TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED COMMON STOCK OF PHARMACYCLICS INC.

Value in Good Management; Biotechs Are Feeling Better: Jim Cramer's Best Blogs

Value in Good Management; Biotechs Are Feeling Better: Jim Cramer's Best Blogs

Catch up on Jim Cramer's thinking over the last week about the sheer power of execution and the much-needed bounceback in biotech.

Jim Cramer's 'Mad Money' Recap: Why Aren't Well-Run Companies Getting Respect?

Jim Cramer's 'Mad Money' Recap: Why Aren't Well-Run Companies Getting Respect?

Cramer says what seems overvalued on paper today might surprise you and be in a whole new category tomorrow.

Stocks Notch Small Gains Ahead of February Jobs Report

Stocks Notch Small Gains Ahead of February Jobs Report

Stocks manage to close with gains on Thursday, but just barely ahead of the February jobs report on Friday

Stocks' Gains Are Limited in Lead-Up to February Jobs Report

Stocks' Gains Are Limited in Lead-Up to February Jobs Report

Stocks regain positive momentum by mid-afternoon. Weaker-than-expected domestic data and the materials sector kept gains limited.

Deutsche Says AbbVie Deal Positive, While Piper Calls Price Too High

Deutsche Says AbbVie Deal Positive, While Piper Calls Price Too High

AbbVie agreed to buy Pharmacyclics for $261.25 per share, or $21B, the companies announced late last night.